AREDS 2 vs AREDS 3: Key Differences Explained (2026)
If you or someone you love has been diagnosed with age-related macular degeneration (AMD), you've almost certainly encountered the AREDS 2 formula. It's been the gold standard in AMD supplementation for over a decade — recommended by ophthalmologists worldwide based on one of the most rigorous clinical trials in eye health history.
But recently, a new term has been appearing in eye doctors' offices and on supplement shelves: AREDS 3. Naturally, patients want to know: what changed? Should they switch? Is newer automatically better?
Here's a clear, clinical breakdown.
What is AREDS 2?
AREDS 2 stands for the Age-Related Eye Disease Study 2 — a major clinical trial sponsored by the National Eye Institute that ran from 2006 to 2012. The study tested modifications to the original AREDS formula to see if they could improve outcomes for patients with intermediate or advanced AMD.
The final AREDS 2 formula contains: Vitamin C (500mg), Vitamin E (400 IU), Lutein (10mg), Zeaxanthin (2mg), Zinc (80mg), and Copper (2mg). Two key changes from AREDS 1: beta-carotene was replaced with lutein and zeaxanthin (safer for smokers), and the zinc dose remained the same. The study found this formula reduced the risk of AMD progression to advanced stages by about 25% over five years.
What is AREDS 3?
AREDS 3 is an ongoing clinical trial — not yet a finalized formula available to the public in the way AREDS 2 is. It's also sponsored by the National Eye Institute and is currently investigating whether additional nutrients, particularly omega-3 fatty acids (DHA and EPA) and modifications to zinc dosage, can further improve outcomes beyond what AREDS 2 achieved.
It's important to understand: AREDS 3 is still a study in progress. There is no officially published "AREDS 3 formula" in the same completed, peer-reviewed sense as AREDS 2. Some supplement brands use "AREDS 3" in their marketing to signal a more advanced formula, but this reflects product positioning more than a completed clinical standard.
What's actually different between AREDS 2 and AREDS 3?
The primary areas being explored in AREDS 3 include:
1. Omega-3 fatty acids (DHA/EPA)
The AREDS 2 trial actually tested omega-3s as an add-on and found they did not provide additional benefit for AMD progression at the doses used. AREDS 3 is re-examining this, using different dosing strategies and focusing on subgroups of patients who may benefit more.
2. Lower zinc dosage
AREDS 2 used 80mg of zinc — a high dose that some researchers believe may cause gastrointestinal side effects or interfere with copper absorption. AREDS 3 is investigating whether a lower zinc dose (25mg) is equally effective with fewer side effects.
3. Genetic subgroup analysis
One of the most significant focuses of AREDS 3 is understanding whether specific genetic variants (particularly CFH genotype) influence how well patients respond to zinc. Early AREDS 2 analysis suggested some genetic profiles may not benefit — or could be harmed — by high zinc doses. AREDS 3 aims to clarify this.
Should you switch from AREDS 2 to AREDS 3?
For most patients: not yet, and not without talking to your ophthalmologist.
AREDS 2 remains the only formula with a completed, large-scale randomized controlled trial demonstrating a 25% reduction in AMD progression. Until AREDS 3 publishes its final results, there is no clinical evidence that any "AREDS 3" labeled supplement outperforms the established AREDS 2 formula.
If you are already taking an AREDS 2-based supplement and tolerating it well, continuing is the evidence-based choice. The more important factors than formula generation are consistency (taking your supplement every day), timing (taking it with a fat-containing meal for optimal absorption), zinc dose tolerance, and smoker status.
What does MacuRest do differently?
MacuRest is built on the AREDS 2 foundation — the proven formula — with one meaningful addition that no standard AREDS 2 product includes: 5mg of melatonin.
Emerging research suggests melatonin plays a neuroprotective role in retinal health, particularly in slowing the oxidative stress that drives AMD progression. The retinal pigment epithelium undergoes its most important repair work overnight. MacuRest is designed to be taken in the evening so the AREDS 2 nutrients are present in your system during this critical window, with melatonin directly supporting that overnight repair process.
Frequently asked questions
Is AREDS 3 better than AREDS 2?
Not proven to be — yet. AREDS 3 is an ongoing trial. Until results are published, AREDS 2 remains the only formula with completed clinical evidence for AMD benefit.
What did AREDS 3 change from AREDS 2?
AREDS 3 is primarily investigating zinc dosage reduction, omega-3 addition, and genetic subgroup response. Final results are not yet published.
Should AMD patients take AREDS 2 or AREDS 3?
Follow your ophthalmologist's recommendation. In 2026, the clinical standard remains AREDS 2. A formula inspired by AREDS 2, taken consistently with food each evening, is the most evidence-based approach available.
Does MacuRest use AREDS 2 or AREDS 3?
MacuRest is built on an AREDS 2-inspired foundation, combined with melatonin to support the eye's overnight repair cycle. It does not use unverified "AREDS 3" marketing — its ingredients are grounded in completed clinical research.
This article is for informational purposes only and does not constitute medical advice. Patients with AMD should work with a licensed ophthalmologist to determine the right supplement protocol for their specific stage of disease and health history.